PARP inhibitors / Rocket Pharma - LARVOL DELTA

How PARPs Have Changed the Ovarian Cancer Clinical Landscape (Oncology Business Review) - "....Welcome, everyone. My name is Dr. Rob Coleman...And it's great to be with my two very dear friends....We're gonna talk PARP. This is obviously a great topic for us. We've all given lots of lectures about PARP and I think we've all appreciated the impact this compound has had in our treatment environment. And of course, we're spreading it like peanut butter all over in different parts of different malignancies....Dr. Moore: So it was a positive study. And I’m not trying to criticize the PI or the design, and it is exciting and it’s incredibly important data. So does PARP after PARP work?...Dr. Herzog: Yeah. And I’m hopeful that we’ll have some more data actually pulled out from our ARIEL3 experience that actually addresses that topic. I think it’ll be quite informative. I think we need to know what those expectations are, and I think you mentioned it. It’d be nice to see it illustrated well from a well-controlled trial."

Video

PARP Inhibitors Help Ovarian Cancer Survivors Live Longer – and Better – Without Disease Progression (Cure Today) - '"We don't have long enough data yet to know if this is also going to translate into longer overall survival,' Dr. Floortje Backes...said in an interview with CURE. 'But so far we do know, that when you take this medication, it adds several months to almost, or more, than a year for the cancer to come back."

Interview • Media quote

PARP Inhibitors in Advanced Ovarian Cancer (PracticeUpdate) - "Dr. Westin: PARP inhibitors are here to stay for the treatment of ovarian cancer, and we have a number of different potential places where we can utilize them. I think that the majority of us now are looking to see where they fit best. So we have indications to use PARP inhibitors, both alone as well as in combination, with antiangiogenic agents in frontline maintenance. It's clear that the biggest benefit to PARP inhibitors as a maintenance is in those patients that have a biomarker, whether that's a BRCA mutation, germline or somatic, or in patients who have been identified as having homologous or combination deficient disease. There still appears to be some benefit to patients that have homologous or combination proficient disease, but it's quite short lived."

Interview • Video

Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells. (Oncogene) - 4-OH tamoxifen when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP & DNA fragmentation to inhibit cologenic growth of MCF7 cells & Tamoxifen-resistant MCF7 cells, respectively

Preclinical-animal • Preclinical-other • Oncology

Developing rational drug combination strategies for PARP inhibitors (ASCO 2012) - Presentation time: Monday June 4, 8:00 AM to 12:00 PM; Promising combinations of PARP inhibitors with temozolomide, CHK1 inhibitors, ATM inhibitors and other agents found

Preclinical-other • Oncology

"Preferably a PARP inhibitor or else platinum based chemotherapy @sgkssg @PCFnews @apccc17 for BRCAness prostate cancer" - neerajaiims

Biosimilar • Genito-urinary Cancer • Oncology • Prostate Cancer

Poly(ADP-ribosylation) and neoplastic transformation:Effect of PARP inhibitors (Curr Pharm Biotechnol) - PARP-1 & PARP-2 expression increases during neoplastic transformation, together with the basal levels of poly(ADP-ribosylation); Greater effect of the PARP inhibitor 3-aminobenzamide on cellular viability in neoplastically transformed cells

Preclinical-other • Oncology

Clinically relevant mutations in lung cancer: A primer (PracticeUpdate) - "Dr. Horn: That’s a great question because it’s something that keeps expanding. So we know that all patients with stage 4 non-small cell lung cancer should have upfront molecular testing, as well as PD-L1 testing. It’s important to remember, though, that if a patient has a driver mutation that’s actually more important than their PD-L1 expression, and that should be what you base therapy on....So, if a patient is negative on plasma, you should go on to get to a tissue biopsy because that really may help you direct therapy."

Interview • Video

A New Hope for Pancreatic Cancer: PARP Inhibition in Tumors With BRCA Mutations (Clinical Care Options) - "Released: March 8, 2019; Expiration: March 7, 2020; Upon completion of this activity, participants should be able to: Describe the rationale for assessing BRCA1/2 and other DNA damage repair gene alterations in pancreatic...Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitors as monotherapy or in combination with other agents in pancreatic ductal adenocarcinoma."

Online CME